Information Provided By: 
Fly News Breaks for March 18, 2019
EXEL
Mar 18, 2019 | 07:33 EDT
As previously reported, Morgan Stanley analyst Jeffrey Hung upgraded Exelixis to Equal Weight from Underweight, citing his view there is limited downside risk for the stock ahead of the cabozantinib/nivolumab data from CheckMate 9ER later this year. Additionally, cabozantinib scripts are looking better in 2019 and Hung sees multiple ways this trend could continue, he tells investors. Hung raised his price target on Exelixis shares to $28 from $20.
News For EXEL From the Last 2 Days
There are no results for your query EXEL
